【財訊快報／記者何美如報導】朗齊生醫*(6876)赴瑞士日內瓦參加外交部舉辦的「2026年臺灣智慧醫療與健康產業展」，為本次參展臺灣企業中唯一的新藥公司，向國際展現朗齊新藥研發成果，並開拓更多國際合作契機。自主開發新成分新藥LXP103在治療肥胖與代謝疾病方面深具潛力，未來可望應用於體重管理、代謝疾病治療，並作為現有療法之輔助應用，預計於年底前向美國FDA提出IND申請。
外交部於5月17-19日第79屆世界衛生大會（WHA）期間，在全球領導者齊聚的瑞士日內瓦推出「臺灣智慧醫療與健康科技展」，邀集國內超過30家醫療院所、智慧醫療設備廠商及藥廠組成代表團，朗齊董事長王繼賢榮膺本次代表團副團長，參與此次日內瓦的重要國際活動，代表臺灣生醫產業展現在「智慧、創新、韌性醫療」三大核心主題下的世界級實力。
王繼賢於開幕儀式上致詞表示，臺灣已建立起一個具備高度競爭力與活力的生醫產業生態系，結合世界級的研究機構與高效率的開發環境，讓創新能夠快速從研究端走向實際應用。朗齊生醫致力於推動創新藥物開發，兼顧科學嚴謹性與臨床實際價值，持續將前瞻研究轉化為具體可行的治療方案。目前朗齊主要藥物技術為LXP103以代謝機制重新定義體重管理議題。透過此次出訪，我們期待與全球夥伴建立連結，拓展合作機會，將臺灣的創新能量推向國際舞台。
總經理陳丘泓進一步介紹，自主開發的新成分新藥LXP103，具備新物質專利，並具有調節脂肪細胞代謝之潛力，具備安全性佳、半衰期長，以及藥物容易分布至周邊組織等特性。在肥胖實驗動物模式的大鼠試驗結果顯示，並展現長期體重控制效果；目前未觀察到明顯食慾抑制、發炎或毒性風險，相關數據進一步支持LXP103於肥胖與代謝疾病治療領域之開發潛力。朗齊與國內權威科學家團隊合作，將進一步以全身減脂、對抗復胖等方向進行第二階段動物實驗，以確立後續適應症布局，預計年底前向美國FDA提出IND申請。
**[Wealth News / Reporter He Meiru]** Langqi Biomedical (6876) has traveled to Geneva, Switzerland, to participate in the “2026 Taiwan Smart Medical and Health Industry Exhibition” organized by the Ministry of Foreign Affairs (MOFA). As the only new drug development company among the participating Taiwanese enterprises, Langqi is showcasing its novel drug R&D achievements to the international community and exploring further opportunities for global collaboration. Its self-developed New Chemical Entity (NCE) drug, LXP103, holds great potential in treating obesity and metabolic diseases. In the future, it is expected to be applied in weight management, the treatment of metabolic diseases, and as an adjunctive therapy to existing treatments. The company plans to submit an Investigational New Drug (IND) application to the US FDA by the end of this year.
During the 79th World Health Assembly (WHA) from May 17 to 19, MOFA launched the “Taiwan Smart Medical and Health Technology Exhibition” in Geneva, Switzerland, where global leaders have gathered. The ministry invited a delegation of over 30 domestic medical institutions, smart medical equipment manufacturers, and pharmaceutical companies. Wang Ji-xian, Chairman of Langqi Biomedical, was honored to serve as the deputy leader of the delegation. Participating in this major international event in Geneva, he represented Taiwan’s biomedical industry, showcasing its world-class capabilities under the three core themes: “Smart, Innovative, and Resilient Healthcare.”
In his speech at the opening ceremony, Wang Ji-xian stated that Taiwan has established a highly competitive and dynamic biomedical industry ecosystem. By combining world-class research institutions with an efficient development environment, innovation can rapidly transition from the research stage to practical application. Langqi Biomedical is dedicated to advancing innovative drug development, balancing scientific rigor with clinical value, and continuously transforming forward-looking research into concrete, viable therapeutic solutions. Currently, Langqi’s primary drug technology is LXP103, which redefines weight management through metabolic mechanisms. Through this visit, the company looks forward to connecting with global partners, expanding collaboration opportunities, and propelling Taiwan’s innovative energy onto the international stage.
General Manager Chen Qiu-hong further introduced that the self-developed NCE drug LXP103 holds a new substance patent and possesses the potential to regulate fat cell (adipocyte) metabolism. It features an excellent safety profile, a long half-life, and favorable drug distribution to peripheral tissues. Results from rat trials in an animal model of obesity demonstrated long-term weight control effects. Currently, no significant appetite suppression, inflammation, or toxicity risks have been observed. This data further supports the development potential of LXP103 in the therapeutic areas of obesity and metabolic diseases. In collaboration with a leading team of domestic scientists, Langqi will proceed to the second phase of animal testing, focusing on whole-body fat reduction and combating weight rebound, to establish its subsequent strategy for clinical indications. The company expects to submit an IND application to the US FDA by the end of the year.
